Compare CRNC & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNC | CTNM |
|---|---|---|
| Founded | 2020 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 430.2M | 489.4M |
| IPO Year | 2019 | 2024 |
| Metric | CRNC | CTNM |
|---|---|---|
| Price | $10.43 | $11.53 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $10.25 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 1.3M | 149.1K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.95 | 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $251,781,000.00 | N/A |
| Revenue This Year | $27.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.85 | $3.57 |
| 52 Week High | $13.74 | $16.33 |
| Indicator | CRNC | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 33.95 |
| Support Level | $9.06 | $10.17 |
| Resistance Level | $11.49 | $13.26 |
| Average True Range (ATR) | 0.94 | 0.74 |
| MACD | -0.03 | -0.22 |
| Stochastic Oscillator | 34.47 | 0.58 |
Cerence Inc is a United States-based software company. It is involved in developing mobility-based solutions for drivers and their cars. The customers include all automobile original equipment manufacturers, or OEMs, or their tier 1 suppliers. The company's revenue is generated by selling software licenses and cloud-connected services. Geographically, it derives a majority of its revenue from the United States and also has a presence in Other Americas; Germany; Other Europe, the Middle East, Africa; Japan, and Other Asia-Pacific.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.